Review



tp 0903  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    MedChemExpress tp 0903
    A Structure of <t>TP-0903.</t> B – D Normal proximal tubular HK-2 and NB SH-SY5Y and Neuro-2a cells were treated with TP-0903 at serial concentrations for 24 h, and then the cell growth was determined using MTT assay. Cell growth was presented as percentage of control (0 μM, 100%). E Apoptosis assay using Annexin V/PI staining and flow cytometric analysis, ( F ) mitochondrial membrane potential (MMP) analysis, or ( G ) Western blot for apoptotic signaling cascade. Quantitative analysis of apoptotic cells or loss of MMP cells was presented as a percentage of total cells. Protein levels were semi-quantitated by densitometric analysis. GAPDH was used as internal control. * and ** P < 0.05 and P < 0.01 as compared to control.
    Tp 0903, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 10 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tp+0903/Dubermatinib/pmc12350951-177-0-5
    Average 94 stars, based on 10 article reviews
    tp 0903 - by Bioz Stars, 2026-09
    94/100 stars

    Images

    1) Product Images from "AXL tyrosine kinase inhibitor TP-0903 induces ROS trigger neuroblastoma cell apoptosis via targeting the miR-335-3p/DKK1 expression"

    Article Title: AXL tyrosine kinase inhibitor TP-0903 induces ROS trigger neuroblastoma cell apoptosis via targeting the miR-335-3p/DKK1 expression

    Journal: Cell Death Discovery

    doi: 10.1038/s41420-025-02681-9

    A Structure of TP-0903. B – D Normal proximal tubular HK-2 and NB SH-SY5Y and Neuro-2a cells were treated with TP-0903 at serial concentrations for 24 h, and then the cell growth was determined using MTT assay. Cell growth was presented as percentage of control (0 μM, 100%). E Apoptosis assay using Annexin V/PI staining and flow cytometric analysis, ( F ) mitochondrial membrane potential (MMP) analysis, or ( G ) Western blot for apoptotic signaling cascade. Quantitative analysis of apoptotic cells or loss of MMP cells was presented as a percentage of total cells. Protein levels were semi-quantitated by densitometric analysis. GAPDH was used as internal control. * and ** P < 0.05 and P < 0.01 as compared to control.
    Figure Legend Snippet: A Structure of TP-0903. B – D Normal proximal tubular HK-2 and NB SH-SY5Y and Neuro-2a cells were treated with TP-0903 at serial concentrations for 24 h, and then the cell growth was determined using MTT assay. Cell growth was presented as percentage of control (0 μM, 100%). E Apoptosis assay using Annexin V/PI staining and flow cytometric analysis, ( F ) mitochondrial membrane potential (MMP) analysis, or ( G ) Western blot for apoptotic signaling cascade. Quantitative analysis of apoptotic cells or loss of MMP cells was presented as a percentage of total cells. Protein levels were semi-quantitated by densitometric analysis. GAPDH was used as internal control. * and ** P < 0.05 and P < 0.01 as compared to control.

    Techniques Used: MTT Assay, Control, Apoptosis Assay, Staining, Membrane, Western Blot

    Cells were treated with 100 nM TP-0903 for 24 h, and then subjected to total RNA extraction and gene expression analysis by RNA-seq analysis. A The heatmap of differentially expressed genes (DEGs) with -2≤ log 2 FC ≤ 2 in response to TP-0903 treatment. B The top 10 biological processes affected by the DEGs using Gene ontology analysis. P -values < 0.05 were indicated as red color. Cells were treated with 100 nM TP-0903 for 24 h, and then subjected to assessment of ( C ) protein levels or ( D ) mRNA expression levels by Western blotting or qRT-PCR analysis, respectively. E Protein levels and ( F ) mRNA expression levels of DKK1 among HK2 (Normal), Neuro-2a, and SH-SY5Y cells using Western blot and qRT-PCR, respectively. ** P < 0.01 as compared to control. G Violin plots of DKK1 gene expression in paired normal (green) and NB tumor (red) gene array data from the TNMplot database.
    Figure Legend Snippet: Cells were treated with 100 nM TP-0903 for 24 h, and then subjected to total RNA extraction and gene expression analysis by RNA-seq analysis. A The heatmap of differentially expressed genes (DEGs) with -2≤ log 2 FC ≤ 2 in response to TP-0903 treatment. B The top 10 biological processes affected by the DEGs using Gene ontology analysis. P -values < 0.05 were indicated as red color. Cells were treated with 100 nM TP-0903 for 24 h, and then subjected to assessment of ( C ) protein levels or ( D ) mRNA expression levels by Western blotting or qRT-PCR analysis, respectively. E Protein levels and ( F ) mRNA expression levels of DKK1 among HK2 (Normal), Neuro-2a, and SH-SY5Y cells using Western blot and qRT-PCR, respectively. ** P < 0.01 as compared to control. G Violin plots of DKK1 gene expression in paired normal (green) and NB tumor (red) gene array data from the TNMplot database.

    Techniques Used: RNA Extraction, Gene Expression, RNA Sequencing, Expressing, Western Blot, Quantitative RT-PCR, Control

    Cells were transfected with siRNA against DKK1 (si-DKK1), treated with 50 nM TP-0903 for 24 h, and subjected to ( A ) immunodetection of cleaved PARP (C-PARP), cleaved caspase-3 (C-Caspase-3), and DKK1; ( B ) cell viability assay; or ( C ) cell apoptosis assay using Annexin V/PI staining and flow cytometric analysis. ** P < 0.01 as compared to control (si-NC, 0 nM). # P < 0.05 as compared to TP-0903 alone (50 nM). D Binding mode for docked ligand TP-0903 (cyan) was shown as stick representation in DKK1 (left panel). Structural domains of DKK1 and the amino acid residues interaction with TP-0903 were indicated. Binding affinity between TP-0903 and DKK1 was −6.0 kcal/mol.
    Figure Legend Snippet: Cells were transfected with siRNA against DKK1 (si-DKK1), treated with 50 nM TP-0903 for 24 h, and subjected to ( A ) immunodetection of cleaved PARP (C-PARP), cleaved caspase-3 (C-Caspase-3), and DKK1; ( B ) cell viability assay; or ( C ) cell apoptosis assay using Annexin V/PI staining and flow cytometric analysis. ** P < 0.01 as compared to control (si-NC, 0 nM). # P < 0.05 as compared to TP-0903 alone (50 nM). D Binding mode for docked ligand TP-0903 (cyan) was shown as stick representation in DKK1 (left panel). Structural domains of DKK1 and the amino acid residues interaction with TP-0903 were indicated. Binding affinity between TP-0903 and DKK1 was −6.0 kcal/mol.

    Techniques Used: Transfection, Immunodetection, Viability Assay, Apoptosis Assay, Staining, Control, Binding Assay

    A Predicted binding site of miR-335-3p on 3’UTR of DKK1 gene. B Cells were treated with serial concentrations of TP-0903 for 24 h and subjected to assess miR-335-3p expression level by qRT-PCR. Neuro-2a cells were transfected with control-mimic or miR-335-mimic, treated with TP-0903, and subjected to ( C ) immunodetection of DKK1 and cleaved PARP (C-PARP) using Western blot analysis, ( D ) cell viability assay, ( E ) qRT-PCR to determine miR-335-3p expression level, ( F ) quantitation of signals on Western blots, or ( G ) cell apoptosis assay using Annexin V/PI staining and flow cytometric analysis. ** P < 0.01 as compared to control. # P < 0.05 as compared to TP-0903 alone (50 nM).
    Figure Legend Snippet: A Predicted binding site of miR-335-3p on 3’UTR of DKK1 gene. B Cells were treated with serial concentrations of TP-0903 for 24 h and subjected to assess miR-335-3p expression level by qRT-PCR. Neuro-2a cells were transfected with control-mimic or miR-335-mimic, treated with TP-0903, and subjected to ( C ) immunodetection of DKK1 and cleaved PARP (C-PARP) using Western blot analysis, ( D ) cell viability assay, ( E ) qRT-PCR to determine miR-335-3p expression level, ( F ) quantitation of signals on Western blots, or ( G ) cell apoptosis assay using Annexin V/PI staining and flow cytometric analysis. ** P < 0.01 as compared to control. # P < 0.05 as compared to TP-0903 alone (50 nM).

    Techniques Used: Binding Assay, Expressing, Quantitative RT-PCR, Transfection, Control, Immunodetection, Western Blot, Viability Assay, Quantitation Assay, Apoptosis Assay, Staining

    A Cells were treated with TP-0903 for 24 h and subjected to ROS assay. Cells were treated with 50 nM TP-0903 or TP-0903 combined with NAC for 24 h and subjected to ( B ) ROS assay, ( C ) apoptosis assay using Annexin V/PI staining and flow cytometric analysis, ( D ) immunodetection of C-PARP and DKK1 by Western blot, or ( E ) qRT-PCR to determine miR-335-3p expression level. GAPDH was used as internal control. Signals were semi-quantitated by densitometric analysis. ** P < 0.01 as compared to control. # P < 0.05 as compared to TP-0903 alone (50 nM). Scale bar=20 μm.
    Figure Legend Snippet: A Cells were treated with TP-0903 for 24 h and subjected to ROS assay. Cells were treated with 50 nM TP-0903 or TP-0903 combined with NAC for 24 h and subjected to ( B ) ROS assay, ( C ) apoptosis assay using Annexin V/PI staining and flow cytometric analysis, ( D ) immunodetection of C-PARP and DKK1 by Western blot, or ( E ) qRT-PCR to determine miR-335-3p expression level. GAPDH was used as internal control. Signals were semi-quantitated by densitometric analysis. ** P < 0.01 as compared to control. # P < 0.05 as compared to TP-0903 alone (50 nM). Scale bar=20 μm.

    Techniques Used: ROS Assay, Apoptosis Assay, Staining, Immunodetection, Western Blot, Quantitative RT-PCR, Expressing, Control

    Balb/c nude mice were inoculated with Neuro-2a cells, and then oral administration of PBS or TP-0903 (10 mg/kg) every 3 days for 20 days. A Representative tumors and ( C ) tumor weights in xenografted mice. Changes in ( B ) tumor volume and ( D ) mouse body weights during the 20-day treatment period. Tumors were acquired and subjected to ( E ) Western blot or ( F ) qRT-PCR to assess DKK1 protein and mRNA expression level, respectively. G IHC assay to assess cell proliferation and DKK1 expression in tumor tissues. H H&E staining to assess tissue morphology. * and **, P < 0.05 and P < 0.01 as compared to control group.
    Figure Legend Snippet: Balb/c nude mice were inoculated with Neuro-2a cells, and then oral administration of PBS or TP-0903 (10 mg/kg) every 3 days for 20 days. A Representative tumors and ( C ) tumor weights in xenografted mice. Changes in ( B ) tumor volume and ( D ) mouse body weights during the 20-day treatment period. Tumors were acquired and subjected to ( E ) Western blot or ( F ) qRT-PCR to assess DKK1 protein and mRNA expression level, respectively. G IHC assay to assess cell proliferation and DKK1 expression in tumor tissues. H H&E staining to assess tissue morphology. * and **, P < 0.05 and P < 0.01 as compared to control group.

    Techniques Used: Western Blot, Quantitative RT-PCR, Expressing, Staining, Control

    TP-0903 promotes ROS generation, upregulates miR-335-3p expression, consequently downregulating DKK1 expression and leading to cell apoptosis.
    Figure Legend Snippet: TP-0903 promotes ROS generation, upregulates miR-335-3p expression, consequently downregulating DKK1 expression and leading to cell apoptosis.

    Techniques Used: Expressing

    Related Articles

    MTT Assay:

    Article Title: AXL tyrosine kinase inhibitor TP-0903 induces ROS trigger neuroblastoma cell apoptosis via targeting the miR-335-3p/DKK1 expression
    Article Snippet: TP-0903 (HY-12963) was purchased from MedChemExpress.. Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).

    Article Title: Mesenchymal-epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate.
    Article Snippet: Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section.. After three days of incubation, the medium was removed.After three days of incubation, the medium was removed.

    Article Title: Mesenchymal–epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate
    Article Snippet: (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays. .. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section. .. After three days of incubation, the medium was removed.

    Article Title: TP-0903 is active in models of drug-resistant acute myeloid leukemia
    Article Snippet: Antibodies against FLT3 (3462; clone 8F2), phospho-FLT3 (3464; clone 30D4), STAT5 (94025; clone D206Y), phospho-STAT5 (4322; clone D47E7), AKT (4691; clone C67E7), phospho-AKT (4060; clone D9E), ERK1/2 (4695; clone 137F5), phospho-EKR1/2 (4370; clone D.13.14.4E), S6K (2708; clone 49D7), phospho-S6K (97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST).(97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST). ... Drugs were obtained from the following sources: TP-0903 (Tolero Pharmaceuticals), gilteritinib (ChemieTek), crenolanib (AROG Pharmaceuticals LLC), midostaurin (LC Laboratories), quizartinib (ChemieTek), sorafenib (LC Laboratories), and RG-7388 (MedChemExpress).. Human and mouse cytokines were purchased from Peprotech.Human and mouse cytokines were purchased from Peprotech.

    Control:

    Article Title: AXL tyrosine kinase inhibitor TP-0903 induces ROS trigger neuroblastoma cell apoptosis via targeting the miR-335-3p/DKK1 expression
    Article Snippet: TP-0903 (HY-12963) was purchased from MedChemExpress.. Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).

    Article Title: Mesenchymal-epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate.
    Article Snippet: Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section.. After three days of incubation, the medium was removed.After three days of incubation, the medium was removed.

    Article Title: Mesenchymal–epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate
    Article Snippet: (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays. .. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section. .. After three days of incubation, the medium was removed.

    Article Title: TP-0903 is active in models of drug-resistant acute myeloid leukemia
    Article Snippet: Antibodies against FLT3 (3462; clone 8F2), phospho-FLT3 (3464; clone 30D4), STAT5 (94025; clone D206Y), phospho-STAT5 (4322; clone D47E7), AKT (4691; clone C67E7), phospho-AKT (4060; clone D9E), ERK1/2 (4695; clone 137F5), phospho-EKR1/2 (4370; clone D.13.14.4E), S6K (2708; clone 49D7), phospho-S6K (97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST).(97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST). ... Drugs were obtained from the following sources: TP-0903 (Tolero Pharmaceuticals), gilteritinib (ChemieTek), crenolanib (AROG Pharmaceuticals LLC), midostaurin (LC Laboratories), quizartinib (ChemieTek), sorafenib (LC Laboratories), and RG-7388 (MedChemExpress).. Human and mouse cytokines were purchased from Peprotech.Human and mouse cytokines were purchased from Peprotech.

    Apoptosis Assay:

    Article Title: AXL tyrosine kinase inhibitor TP-0903 induces ROS trigger neuroblastoma cell apoptosis via targeting the miR-335-3p/DKK1 expression
    Article Snippet: TP-0903 (HY-12963) was purchased from MedChemExpress.. Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).

    Article Title: Mesenchymal-epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate.
    Article Snippet: Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section.. After three days of incubation, the medium was removed.After three days of incubation, the medium was removed.

    Article Title: Mesenchymal–epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate
    Article Snippet: (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays. .. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section. .. After three days of incubation, the medium was removed.

    Article Title: TP-0903 is active in models of drug-resistant acute myeloid leukemia
    Article Snippet: Antibodies against FLT3 (3462; clone 8F2), phospho-FLT3 (3464; clone 30D4), STAT5 (94025; clone D206Y), phospho-STAT5 (4322; clone D47E7), AKT (4691; clone C67E7), phospho-AKT (4060; clone D9E), ERK1/2 (4695; clone 137F5), phospho-EKR1/2 (4370; clone D.13.14.4E), S6K (2708; clone 49D7), phospho-S6K (97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST).(97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST). ... Drugs were obtained from the following sources: TP-0903 (Tolero Pharmaceuticals), gilteritinib (ChemieTek), crenolanib (AROG Pharmaceuticals LLC), midostaurin (LC Laboratories), quizartinib (ChemieTek), sorafenib (LC Laboratories), and RG-7388 (MedChemExpress).. Human and mouse cytokines were purchased from Peprotech.Human and mouse cytokines were purchased from Peprotech.

    Staining:

    Article Title: AXL tyrosine kinase inhibitor TP-0903 induces ROS trigger neuroblastoma cell apoptosis via targeting the miR-335-3p/DKK1 expression
    Article Snippet: TP-0903 (HY-12963) was purchased from MedChemExpress.. Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).

    Article Title: Mesenchymal-epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate.
    Article Snippet: Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section.. After three days of incubation, the medium was removed.After three days of incubation, the medium was removed.

    Article Title: Mesenchymal–epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate
    Article Snippet: (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays. .. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section. .. After three days of incubation, the medium was removed.

    Article Title: TP-0903 is active in models of drug-resistant acute myeloid leukemia
    Article Snippet: Antibodies against FLT3 (3462; clone 8F2), phospho-FLT3 (3464; clone 30D4), STAT5 (94025; clone D206Y), phospho-STAT5 (4322; clone D47E7), AKT (4691; clone C67E7), phospho-AKT (4060; clone D9E), ERK1/2 (4695; clone 137F5), phospho-EKR1/2 (4370; clone D.13.14.4E), S6K (2708; clone 49D7), phospho-S6K (97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST).(97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST). ... Drugs were obtained from the following sources: TP-0903 (Tolero Pharmaceuticals), gilteritinib (ChemieTek), crenolanib (AROG Pharmaceuticals LLC), midostaurin (LC Laboratories), quizartinib (ChemieTek), sorafenib (LC Laboratories), and RG-7388 (MedChemExpress).. Human and mouse cytokines were purchased from Peprotech.Human and mouse cytokines were purchased from Peprotech.

    Membrane:

    Article Title: AXL tyrosine kinase inhibitor TP-0903 induces ROS trigger neuroblastoma cell apoptosis via targeting the miR-335-3p/DKK1 expression
    Article Snippet: TP-0903 (HY-12963) was purchased from MedChemExpress.. Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).

    Article Title: Mesenchymal-epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate.
    Article Snippet: Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section.. After three days of incubation, the medium was removed.After three days of incubation, the medium was removed.

    Article Title: Mesenchymal–epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate
    Article Snippet: (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays. .. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section. .. After three days of incubation, the medium was removed.

    Article Title: TP-0903 is active in models of drug-resistant acute myeloid leukemia
    Article Snippet: Antibodies against FLT3 (3462; clone 8F2), phospho-FLT3 (3464; clone 30D4), STAT5 (94025; clone D206Y), phospho-STAT5 (4322; clone D47E7), AKT (4691; clone C67E7), phospho-AKT (4060; clone D9E), ERK1/2 (4695; clone 137F5), phospho-EKR1/2 (4370; clone D.13.14.4E), S6K (2708; clone 49D7), phospho-S6K (97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST).(97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST). ... Drugs were obtained from the following sources: TP-0903 (Tolero Pharmaceuticals), gilteritinib (ChemieTek), crenolanib (AROG Pharmaceuticals LLC), midostaurin (LC Laboratories), quizartinib (ChemieTek), sorafenib (LC Laboratories), and RG-7388 (MedChemExpress).. Human and mouse cytokines were purchased from Peprotech.Human and mouse cytokines were purchased from Peprotech.

    Western Blot:

    Article Title: AXL tyrosine kinase inhibitor TP-0903 induces ROS trigger neuroblastoma cell apoptosis via targeting the miR-335-3p/DKK1 expression
    Article Snippet: TP-0903 (HY-12963) was purchased from MedChemExpress.. Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).

    Article Title: Mesenchymal-epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate.
    Article Snippet: Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section.. After three days of incubation, the medium was removed.After three days of incubation, the medium was removed.

    Article Title: Mesenchymal–epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate
    Article Snippet: (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays. .. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section. .. After three days of incubation, the medium was removed.

    Article Title: TP-0903 is active in models of drug-resistant acute myeloid leukemia
    Article Snippet: Antibodies against FLT3 (3462; clone 8F2), phospho-FLT3 (3464; clone 30D4), STAT5 (94025; clone D206Y), phospho-STAT5 (4322; clone D47E7), AKT (4691; clone C67E7), phospho-AKT (4060; clone D9E), ERK1/2 (4695; clone 137F5), phospho-EKR1/2 (4370; clone D.13.14.4E), S6K (2708; clone 49D7), phospho-S6K (97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST).(97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST). ... Drugs were obtained from the following sources: TP-0903 (Tolero Pharmaceuticals), gilteritinib (ChemieTek), crenolanib (AROG Pharmaceuticals LLC), midostaurin (LC Laboratories), quizartinib (ChemieTek), sorafenib (LC Laboratories), and RG-7388 (MedChemExpress).. Human and mouse cytokines were purchased from Peprotech.Human and mouse cytokines were purchased from Peprotech.

    RNA Extraction:

    Article Title: AXL tyrosine kinase inhibitor TP-0903 induces ROS trigger neuroblastoma cell apoptosis via targeting the miR-335-3p/DKK1 expression
    Article Snippet: TP-0903 (HY-12963) was purchased from MedChemExpress.. Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).

    Article Title: Mesenchymal-epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate.
    Article Snippet: Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section.. After three days of incubation, the medium was removed.After three days of incubation, the medium was removed.

    Article Title: Mesenchymal–epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate
    Article Snippet: (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays. .. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section. .. After three days of incubation, the medium was removed.

    Article Title: TP-0903 is active in models of drug-resistant acute myeloid leukemia
    Article Snippet: Antibodies against FLT3 (3462; clone 8F2), phospho-FLT3 (3464; clone 30D4), STAT5 (94025; clone D206Y), phospho-STAT5 (4322; clone D47E7), AKT (4691; clone C67E7), phospho-AKT (4060; clone D9E), ERK1/2 (4695; clone 137F5), phospho-EKR1/2 (4370; clone D.13.14.4E), S6K (2708; clone 49D7), phospho-S6K (97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST).(97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST). ... Drugs were obtained from the following sources: TP-0903 (Tolero Pharmaceuticals), gilteritinib (ChemieTek), crenolanib (AROG Pharmaceuticals LLC), midostaurin (LC Laboratories), quizartinib (ChemieTek), sorafenib (LC Laboratories), and RG-7388 (MedChemExpress).. Human and mouse cytokines were purchased from Peprotech.Human and mouse cytokines were purchased from Peprotech.

    Gene Expression:

    Article Title: AXL tyrosine kinase inhibitor TP-0903 induces ROS trigger neuroblastoma cell apoptosis via targeting the miR-335-3p/DKK1 expression
    Article Snippet: TP-0903 (HY-12963) was purchased from MedChemExpress.. Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).

    Article Title: Mesenchymal-epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate.
    Article Snippet: Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section.. After three days of incubation, the medium was removed.After three days of incubation, the medium was removed.

    Article Title: Mesenchymal–epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate
    Article Snippet: (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays. .. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section. .. After three days of incubation, the medium was removed.

    Article Title: TP-0903 is active in models of drug-resistant acute myeloid leukemia
    Article Snippet: Antibodies against FLT3 (3462; clone 8F2), phospho-FLT3 (3464; clone 30D4), STAT5 (94025; clone D206Y), phospho-STAT5 (4322; clone D47E7), AKT (4691; clone C67E7), phospho-AKT (4060; clone D9E), ERK1/2 (4695; clone 137F5), phospho-EKR1/2 (4370; clone D.13.14.4E), S6K (2708; clone 49D7), phospho-S6K (97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST).(97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST). ... Drugs were obtained from the following sources: TP-0903 (Tolero Pharmaceuticals), gilteritinib (ChemieTek), crenolanib (AROG Pharmaceuticals LLC), midostaurin (LC Laboratories), quizartinib (ChemieTek), sorafenib (LC Laboratories), and RG-7388 (MedChemExpress).. Human and mouse cytokines were purchased from Peprotech.Human and mouse cytokines were purchased from Peprotech.

    RNA Sequencing:

    Article Title: AXL tyrosine kinase inhibitor TP-0903 induces ROS trigger neuroblastoma cell apoptosis via targeting the miR-335-3p/DKK1 expression
    Article Snippet: TP-0903 (HY-12963) was purchased from MedChemExpress.. Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).

    Article Title: Mesenchymal-epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate.
    Article Snippet: Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section.. After three days of incubation, the medium was removed.After three days of incubation, the medium was removed.

    Article Title: Mesenchymal–epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate
    Article Snippet: (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays. .. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section. .. After three days of incubation, the medium was removed.

    Article Title: TP-0903 is active in models of drug-resistant acute myeloid leukemia
    Article Snippet: Antibodies against FLT3 (3462; clone 8F2), phospho-FLT3 (3464; clone 30D4), STAT5 (94025; clone D206Y), phospho-STAT5 (4322; clone D47E7), AKT (4691; clone C67E7), phospho-AKT (4060; clone D9E), ERK1/2 (4695; clone 137F5), phospho-EKR1/2 (4370; clone D.13.14.4E), S6K (2708; clone 49D7), phospho-S6K (97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST).(97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST). ... Drugs were obtained from the following sources: TP-0903 (Tolero Pharmaceuticals), gilteritinib (ChemieTek), crenolanib (AROG Pharmaceuticals LLC), midostaurin (LC Laboratories), quizartinib (ChemieTek), sorafenib (LC Laboratories), and RG-7388 (MedChemExpress).. Human and mouse cytokines were purchased from Peprotech.Human and mouse cytokines were purchased from Peprotech.

    Expressing:

    Article Title: AXL tyrosine kinase inhibitor TP-0903 induces ROS trigger neuroblastoma cell apoptosis via targeting the miR-335-3p/DKK1 expression
    Article Snippet: TP-0903 (HY-12963) was purchased from MedChemExpress.. Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).

    Article Title: Mesenchymal-epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate.
    Article Snippet: Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section.. After three days of incubation, the medium was removed.After three days of incubation, the medium was removed.

    Article Title: Mesenchymal–epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate
    Article Snippet: (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays. .. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section. .. After three days of incubation, the medium was removed.

    Article Title: TP-0903 is active in models of drug-resistant acute myeloid leukemia
    Article Snippet: Antibodies against FLT3 (3462; clone 8F2), phospho-FLT3 (3464; clone 30D4), STAT5 (94025; clone D206Y), phospho-STAT5 (4322; clone D47E7), AKT (4691; clone C67E7), phospho-AKT (4060; clone D9E), ERK1/2 (4695; clone 137F5), phospho-EKR1/2 (4370; clone D.13.14.4E), S6K (2708; clone 49D7), phospho-S6K (97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST).(97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST). ... Drugs were obtained from the following sources: TP-0903 (Tolero Pharmaceuticals), gilteritinib (ChemieTek), crenolanib (AROG Pharmaceuticals LLC), midostaurin (LC Laboratories), quizartinib (ChemieTek), sorafenib (LC Laboratories), and RG-7388 (MedChemExpress).. Human and mouse cytokines were purchased from Peprotech.Human and mouse cytokines were purchased from Peprotech.

    Quantitative RT-PCR:

    Article Title: AXL tyrosine kinase inhibitor TP-0903 induces ROS trigger neuroblastoma cell apoptosis via targeting the miR-335-3p/DKK1 expression
    Article Snippet: TP-0903 (HY-12963) was purchased from MedChemExpress.. Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).

    Article Title: Mesenchymal-epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate.
    Article Snippet: Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section.. After three days of incubation, the medium was removed.After three days of incubation, the medium was removed.

    Article Title: Mesenchymal–epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate
    Article Snippet: (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays. .. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section. .. After three days of incubation, the medium was removed.

    Article Title: TP-0903 is active in models of drug-resistant acute myeloid leukemia
    Article Snippet: Antibodies against FLT3 (3462; clone 8F2), phospho-FLT3 (3464; clone 30D4), STAT5 (94025; clone D206Y), phospho-STAT5 (4322; clone D47E7), AKT (4691; clone C67E7), phospho-AKT (4060; clone D9E), ERK1/2 (4695; clone 137F5), phospho-EKR1/2 (4370; clone D.13.14.4E), S6K (2708; clone 49D7), phospho-S6K (97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST).(97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST). ... Drugs were obtained from the following sources: TP-0903 (Tolero Pharmaceuticals), gilteritinib (ChemieTek), crenolanib (AROG Pharmaceuticals LLC), midostaurin (LC Laboratories), quizartinib (ChemieTek), sorafenib (LC Laboratories), and RG-7388 (MedChemExpress).. Human and mouse cytokines were purchased from Peprotech.Human and mouse cytokines were purchased from Peprotech.

    Transfection:

    Article Title: AXL tyrosine kinase inhibitor TP-0903 induces ROS trigger neuroblastoma cell apoptosis via targeting the miR-335-3p/DKK1 expression
    Article Snippet: TP-0903 (HY-12963) was purchased from MedChemExpress.. Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).

    Article Title: Mesenchymal-epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate.
    Article Snippet: Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section.. After three days of incubation, the medium was removed.After three days of incubation, the medium was removed.

    Article Title: Mesenchymal–epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate
    Article Snippet: (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays. .. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section. .. After three days of incubation, the medium was removed.

    Article Title: TP-0903 is active in models of drug-resistant acute myeloid leukemia
    Article Snippet: Antibodies against FLT3 (3462; clone 8F2), phospho-FLT3 (3464; clone 30D4), STAT5 (94025; clone D206Y), phospho-STAT5 (4322; clone D47E7), AKT (4691; clone C67E7), phospho-AKT (4060; clone D9E), ERK1/2 (4695; clone 137F5), phospho-EKR1/2 (4370; clone D.13.14.4E), S6K (2708; clone 49D7), phospho-S6K (97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST).(97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST). ... Drugs were obtained from the following sources: TP-0903 (Tolero Pharmaceuticals), gilteritinib (ChemieTek), crenolanib (AROG Pharmaceuticals LLC), midostaurin (LC Laboratories), quizartinib (ChemieTek), sorafenib (LC Laboratories), and RG-7388 (MedChemExpress).. Human and mouse cytokines were purchased from Peprotech.Human and mouse cytokines were purchased from Peprotech.

    Immunodetection:

    Article Title: AXL tyrosine kinase inhibitor TP-0903 induces ROS trigger neuroblastoma cell apoptosis via targeting the miR-335-3p/DKK1 expression
    Article Snippet: TP-0903 (HY-12963) was purchased from MedChemExpress.. Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).

    Article Title: Mesenchymal-epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate.
    Article Snippet: Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section.. After three days of incubation, the medium was removed.After three days of incubation, the medium was removed.

    Article Title: Mesenchymal–epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate
    Article Snippet: (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays. .. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section. .. After three days of incubation, the medium was removed.

    Article Title: TP-0903 is active in models of drug-resistant acute myeloid leukemia
    Article Snippet: Antibodies against FLT3 (3462; clone 8F2), phospho-FLT3 (3464; clone 30D4), STAT5 (94025; clone D206Y), phospho-STAT5 (4322; clone D47E7), AKT (4691; clone C67E7), phospho-AKT (4060; clone D9E), ERK1/2 (4695; clone 137F5), phospho-EKR1/2 (4370; clone D.13.14.4E), S6K (2708; clone 49D7), phospho-S6K (97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST).(97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST). ... Drugs were obtained from the following sources: TP-0903 (Tolero Pharmaceuticals), gilteritinib (ChemieTek), crenolanib (AROG Pharmaceuticals LLC), midostaurin (LC Laboratories), quizartinib (ChemieTek), sorafenib (LC Laboratories), and RG-7388 (MedChemExpress).. Human and mouse cytokines were purchased from Peprotech.Human and mouse cytokines were purchased from Peprotech.

    Viability Assay:

    Article Title: AXL tyrosine kinase inhibitor TP-0903 induces ROS trigger neuroblastoma cell apoptosis via targeting the miR-335-3p/DKK1 expression
    Article Snippet: TP-0903 (HY-12963) was purchased from MedChemExpress.. Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).

    Article Title: Mesenchymal-epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate.
    Article Snippet: Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section.. After three days of incubation, the medium was removed.After three days of incubation, the medium was removed.

    Article Title: Mesenchymal–epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate
    Article Snippet: (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays. .. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section. .. After three days of incubation, the medium was removed.

    Article Title: TP-0903 is active in models of drug-resistant acute myeloid leukemia
    Article Snippet: Antibodies against FLT3 (3462; clone 8F2), phospho-FLT3 (3464; clone 30D4), STAT5 (94025; clone D206Y), phospho-STAT5 (4322; clone D47E7), AKT (4691; clone C67E7), phospho-AKT (4060; clone D9E), ERK1/2 (4695; clone 137F5), phospho-EKR1/2 (4370; clone D.13.14.4E), S6K (2708; clone 49D7), phospho-S6K (97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST).(97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST). ... Drugs were obtained from the following sources: TP-0903 (Tolero Pharmaceuticals), gilteritinib (ChemieTek), crenolanib (AROG Pharmaceuticals LLC), midostaurin (LC Laboratories), quizartinib (ChemieTek), sorafenib (LC Laboratories), and RG-7388 (MedChemExpress).. Human and mouse cytokines were purchased from Peprotech.Human and mouse cytokines were purchased from Peprotech.

    Binding Assay:

    Article Title: AXL tyrosine kinase inhibitor TP-0903 induces ROS trigger neuroblastoma cell apoptosis via targeting the miR-335-3p/DKK1 expression
    Article Snippet: TP-0903 (HY-12963) was purchased from MedChemExpress.. Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).

    Article Title: Mesenchymal-epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate.
    Article Snippet: Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section.. After three days of incubation, the medium was removed.After three days of incubation, the medium was removed.

    Article Title: Mesenchymal–epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate
    Article Snippet: (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays. .. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section. .. After three days of incubation, the medium was removed.

    Article Title: TP-0903 is active in models of drug-resistant acute myeloid leukemia
    Article Snippet: Antibodies against FLT3 (3462; clone 8F2), phospho-FLT3 (3464; clone 30D4), STAT5 (94025; clone D206Y), phospho-STAT5 (4322; clone D47E7), AKT (4691; clone C67E7), phospho-AKT (4060; clone D9E), ERK1/2 (4695; clone 137F5), phospho-EKR1/2 (4370; clone D.13.14.4E), S6K (2708; clone 49D7), phospho-S6K (97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST).(97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST). ... Drugs were obtained from the following sources: TP-0903 (Tolero Pharmaceuticals), gilteritinib (ChemieTek), crenolanib (AROG Pharmaceuticals LLC), midostaurin (LC Laboratories), quizartinib (ChemieTek), sorafenib (LC Laboratories), and RG-7388 (MedChemExpress).. Human and mouse cytokines were purchased from Peprotech.Human and mouse cytokines were purchased from Peprotech.

    Quantitation Assay:

    Article Title: AXL tyrosine kinase inhibitor TP-0903 induces ROS trigger neuroblastoma cell apoptosis via targeting the miR-335-3p/DKK1 expression
    Article Snippet: TP-0903 (HY-12963) was purchased from MedChemExpress.. Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).

    Article Title: Mesenchymal-epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate.
    Article Snippet: Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section.. After three days of incubation, the medium was removed.After three days of incubation, the medium was removed.

    Article Title: Mesenchymal–epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate
    Article Snippet: (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays. .. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section. .. After three days of incubation, the medium was removed.

    Article Title: TP-0903 is active in models of drug-resistant acute myeloid leukemia
    Article Snippet: Antibodies against FLT3 (3462; clone 8F2), phospho-FLT3 (3464; clone 30D4), STAT5 (94025; clone D206Y), phospho-STAT5 (4322; clone D47E7), AKT (4691; clone C67E7), phospho-AKT (4060; clone D9E), ERK1/2 (4695; clone 137F5), phospho-EKR1/2 (4370; clone D.13.14.4E), S6K (2708; clone 49D7), phospho-S6K (97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST).(97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST). ... Drugs were obtained from the following sources: TP-0903 (Tolero Pharmaceuticals), gilteritinib (ChemieTek), crenolanib (AROG Pharmaceuticals LLC), midostaurin (LC Laboratories), quizartinib (ChemieTek), sorafenib (LC Laboratories), and RG-7388 (MedChemExpress).. Human and mouse cytokines were purchased from Peprotech.Human and mouse cytokines were purchased from Peprotech.

    ROS Assay:

    Article Title: AXL tyrosine kinase inhibitor TP-0903 induces ROS trigger neuroblastoma cell apoptosis via targeting the miR-335-3p/DKK1 expression
    Article Snippet: TP-0903 (HY-12963) was purchased from MedChemExpress.. Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).

    Article Title: Mesenchymal-epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate.
    Article Snippet: Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section.. After three days of incubation, the medium was removed.After three days of incubation, the medium was removed.

    Article Title: Mesenchymal–epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate
    Article Snippet: (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays. .. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section. .. After three days of incubation, the medium was removed.

    Article Title: TP-0903 is active in models of drug-resistant acute myeloid leukemia
    Article Snippet: Antibodies against FLT3 (3462; clone 8F2), phospho-FLT3 (3464; clone 30D4), STAT5 (94025; clone D206Y), phospho-STAT5 (4322; clone D47E7), AKT (4691; clone C67E7), phospho-AKT (4060; clone D9E), ERK1/2 (4695; clone 137F5), phospho-EKR1/2 (4370; clone D.13.14.4E), S6K (2708; clone 49D7), phospho-S6K (97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST).(97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST). ... Drugs were obtained from the following sources: TP-0903 (Tolero Pharmaceuticals), gilteritinib (ChemieTek), crenolanib (AROG Pharmaceuticals LLC), midostaurin (LC Laboratories), quizartinib (ChemieTek), sorafenib (LC Laboratories), and RG-7388 (MedChemExpress).. Human and mouse cytokines were purchased from Peprotech.Human and mouse cytokines were purchased from Peprotech.

    Phospho-proteomics:

    Article Title: AXL tyrosine kinase inhibitor TP-0903 induces ROS trigger neuroblastoma cell apoptosis via targeting the miR-335-3p/DKK1 expression
    Article Snippet: TP-0903 (HY-12963) was purchased from MedChemExpress.. Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).

    Article Title: Mesenchymal-epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate.
    Article Snippet: Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section.. After three days of incubation, the medium was removed.After three days of incubation, the medium was removed.

    Article Title: Mesenchymal–epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate
    Article Snippet: (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays. .. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section. .. After three days of incubation, the medium was removed.

    Article Title: TP-0903 is active in models of drug-resistant acute myeloid leukemia
    Article Snippet: Antibodies against FLT3 (3462; clone 8F2), phospho-FLT3 (3464; clone 30D4), STAT5 (94025; clone D206Y), phospho-STAT5 (4322; clone D47E7), AKT (4691; clone C67E7), phospho-AKT (4060; clone D9E), ERK1/2 (4695; clone 137F5), phospho-EKR1/2 (4370; clone D.13.14.4E), S6K (2708; clone 49D7), phospho-S6K (97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST).(97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST). ... Drugs were obtained from the following sources: TP-0903 (Tolero Pharmaceuticals), gilteritinib (ChemieTek), crenolanib (AROG Pharmaceuticals LLC), midostaurin (LC Laboratories), quizartinib (ChemieTek), sorafenib (LC Laboratories), and RG-7388 (MedChemExpress).. Human and mouse cytokines were purchased from Peprotech.Human and mouse cytokines were purchased from Peprotech.

    Concentration Assay:

    Article Title: AXL tyrosine kinase inhibitor TP-0903 induces ROS trigger neuroblastoma cell apoptosis via targeting the miR-335-3p/DKK1 expression
    Article Snippet: TP-0903 (HY-12963) was purchased from MedChemExpress.. Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).

    Article Title: Mesenchymal-epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate.
    Article Snippet: Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section.. After three days of incubation, the medium was removed.After three days of incubation, the medium was removed.

    Article Title: Mesenchymal–epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate
    Article Snippet: (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays. .. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section. .. After three days of incubation, the medium was removed.

    Article Title: TP-0903 is active in models of drug-resistant acute myeloid leukemia
    Article Snippet: Antibodies against FLT3 (3462; clone 8F2), phospho-FLT3 (3464; clone 30D4), STAT5 (94025; clone D206Y), phospho-STAT5 (4322; clone D47E7), AKT (4691; clone C67E7), phospho-AKT (4060; clone D9E), ERK1/2 (4695; clone 137F5), phospho-EKR1/2 (4370; clone D.13.14.4E), S6K (2708; clone 49D7), phospho-S6K (97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST).(97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST). ... Drugs were obtained from the following sources: TP-0903 (Tolero Pharmaceuticals), gilteritinib (ChemieTek), crenolanib (AROG Pharmaceuticals LLC), midostaurin (LC Laboratories), quizartinib (ChemieTek), sorafenib (LC Laboratories), and RG-7388 (MedChemExpress).. Human and mouse cytokines were purchased from Peprotech.Human and mouse cytokines were purchased from Peprotech.

    Inhibition:

    Article Title: AXL tyrosine kinase inhibitor TP-0903 induces ROS trigger neuroblastoma cell apoptosis via targeting the miR-335-3p/DKK1 expression
    Article Snippet: TP-0903 (HY-12963) was purchased from MedChemExpress.. Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).

    Article Title: Mesenchymal-epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate.
    Article Snippet: Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section.. After three days of incubation, the medium was removed.After three days of incubation, the medium was removed.

    Article Title: Mesenchymal–epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate
    Article Snippet: (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays. .. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section. .. After three days of incubation, the medium was removed.

    Article Title: TP-0903 is active in models of drug-resistant acute myeloid leukemia
    Article Snippet: Antibodies against FLT3 (3462; clone 8F2), phospho-FLT3 (3464; clone 30D4), STAT5 (94025; clone D206Y), phospho-STAT5 (4322; clone D47E7), AKT (4691; clone C67E7), phospho-AKT (4060; clone D9E), ERK1/2 (4695; clone 137F5), phospho-EKR1/2 (4370; clone D.13.14.4E), S6K (2708; clone 49D7), phospho-S6K (97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST).(97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST). ... Drugs were obtained from the following sources: TP-0903 (Tolero Pharmaceuticals), gilteritinib (ChemieTek), crenolanib (AROG Pharmaceuticals LLC), midostaurin (LC Laboratories), quizartinib (ChemieTek), sorafenib (LC Laboratories), and RG-7388 (MedChemExpress).. Human and mouse cytokines were purchased from Peprotech.Human and mouse cytokines were purchased from Peprotech.

    Cell Culture:

    Article Title: AXL tyrosine kinase inhibitor TP-0903 induces ROS trigger neuroblastoma cell apoptosis via targeting the miR-335-3p/DKK1 expression
    Article Snippet: TP-0903 (HY-12963) was purchased from MedChemExpress.. Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).

    Article Title: Mesenchymal-epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate.
    Article Snippet: Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section.. After three days of incubation, the medium was removed.After three days of incubation, the medium was removed.

    Article Title: Mesenchymal–epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate
    Article Snippet: (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays. .. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section. .. After three days of incubation, the medium was removed.

    Article Title: TP-0903 is active in models of drug-resistant acute myeloid leukemia
    Article Snippet: Antibodies against FLT3 (3462; clone 8F2), phospho-FLT3 (3464; clone 30D4), STAT5 (94025; clone D206Y), phospho-STAT5 (4322; clone D47E7), AKT (4691; clone C67E7), phospho-AKT (4060; clone D9E), ERK1/2 (4695; clone 137F5), phospho-EKR1/2 (4370; clone D.13.14.4E), S6K (2708; clone 49D7), phospho-S6K (97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST).(97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST). ... Drugs were obtained from the following sources: TP-0903 (Tolero Pharmaceuticals), gilteritinib (ChemieTek), crenolanib (AROG Pharmaceuticals LLC), midostaurin (LC Laboratories), quizartinib (ChemieTek), sorafenib (LC Laboratories), and RG-7388 (MedChemExpress).. Human and mouse cytokines were purchased from Peprotech.Human and mouse cytokines were purchased from Peprotech.

    Fluorescence:

    Article Title: AXL tyrosine kinase inhibitor TP-0903 induces ROS trigger neuroblastoma cell apoptosis via targeting the miR-335-3p/DKK1 expression
    Article Snippet: TP-0903 (HY-12963) was purchased from MedChemExpress.. Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).

    Article Title: Mesenchymal-epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate.
    Article Snippet: Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section.. After three days of incubation, the medium was removed.After three days of incubation, the medium was removed.

    Article Title: Mesenchymal–epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate
    Article Snippet: (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays. .. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section. .. After three days of incubation, the medium was removed.

    Article Title: TP-0903 is active in models of drug-resistant acute myeloid leukemia
    Article Snippet: Antibodies against FLT3 (3462; clone 8F2), phospho-FLT3 (3464; clone 30D4), STAT5 (94025; clone D206Y), phospho-STAT5 (4322; clone D47E7), AKT (4691; clone C67E7), phospho-AKT (4060; clone D9E), ERK1/2 (4695; clone 137F5), phospho-EKR1/2 (4370; clone D.13.14.4E), S6K (2708; clone 49D7), phospho-S6K (97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST).(97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST). ... Drugs were obtained from the following sources: TP-0903 (Tolero Pharmaceuticals), gilteritinib (ChemieTek), crenolanib (AROG Pharmaceuticals LLC), midostaurin (LC Laboratories), quizartinib (ChemieTek), sorafenib (LC Laboratories), and RG-7388 (MedChemExpress).. Human and mouse cytokines were purchased from Peprotech.Human and mouse cytokines were purchased from Peprotech.

    Software:

    Article Title: AXL tyrosine kinase inhibitor TP-0903 induces ROS trigger neuroblastoma cell apoptosis via targeting the miR-335-3p/DKK1 expression
    Article Snippet: TP-0903 (HY-12963) was purchased from MedChemExpress.. Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).

    Article Title: Mesenchymal-epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate.
    Article Snippet: Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section.. After three days of incubation, the medium was removed.After three days of incubation, the medium was removed.

    Article Title: Mesenchymal–epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate
    Article Snippet: (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays. .. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section. .. After three days of incubation, the medium was removed.

    Article Title: TP-0903 is active in models of drug-resistant acute myeloid leukemia
    Article Snippet: Antibodies against FLT3 (3462; clone 8F2), phospho-FLT3 (3464; clone 30D4), STAT5 (94025; clone D206Y), phospho-STAT5 (4322; clone D47E7), AKT (4691; clone C67E7), phospho-AKT (4060; clone D9E), ERK1/2 (4695; clone 137F5), phospho-EKR1/2 (4370; clone D.13.14.4E), S6K (2708; clone 49D7), phospho-S6K (97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST).(97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST). ... Drugs were obtained from the following sources: TP-0903 (Tolero Pharmaceuticals), gilteritinib (ChemieTek), crenolanib (AROG Pharmaceuticals LLC), midostaurin (LC Laboratories), quizartinib (ChemieTek), sorafenib (LC Laboratories), and RG-7388 (MedChemExpress).. Human and mouse cytokines were purchased from Peprotech.Human and mouse cytokines were purchased from Peprotech.

    Activity Assay:

    Article Title: AXL tyrosine kinase inhibitor TP-0903 induces ROS trigger neuroblastoma cell apoptosis via targeting the miR-335-3p/DKK1 expression
    Article Snippet: TP-0903 (HY-12963) was purchased from MedChemExpress.. Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).

    Article Title: Mesenchymal-epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate.
    Article Snippet: Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section.. After three days of incubation, the medium was removed.After three days of incubation, the medium was removed.

    Article Title: Mesenchymal–epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate
    Article Snippet: (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays. .. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section. .. After three days of incubation, the medium was removed.

    Article Title: TP-0903 is active in models of drug-resistant acute myeloid leukemia
    Article Snippet: Antibodies against FLT3 (3462; clone 8F2), phospho-FLT3 (3464; clone 30D4), STAT5 (94025; clone D206Y), phospho-STAT5 (4322; clone D47E7), AKT (4691; clone C67E7), phospho-AKT (4060; clone D9E), ERK1/2 (4695; clone 137F5), phospho-EKR1/2 (4370; clone D.13.14.4E), S6K (2708; clone 49D7), phospho-S6K (97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST).(97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST). ... Drugs were obtained from the following sources: TP-0903 (Tolero Pharmaceuticals), gilteritinib (ChemieTek), crenolanib (AROG Pharmaceuticals LLC), midostaurin (LC Laboratories), quizartinib (ChemieTek), sorafenib (LC Laboratories), and RG-7388 (MedChemExpress).. Human and mouse cytokines were purchased from Peprotech.Human and mouse cytokines were purchased from Peprotech.

    Cell Differentiation:

    Article Title: AXL tyrosine kinase inhibitor TP-0903 induces ROS trigger neuroblastoma cell apoptosis via targeting the miR-335-3p/DKK1 expression
    Article Snippet: TP-0903 (HY-12963) was purchased from MedChemExpress.. Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).

    Article Title: Mesenchymal-epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate.
    Article Snippet: Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section.. After three days of incubation, the medium was removed.After three days of incubation, the medium was removed.

    Article Title: Mesenchymal–epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate
    Article Snippet: (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays. .. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section. .. After three days of incubation, the medium was removed.

    Article Title: TP-0903 is active in models of drug-resistant acute myeloid leukemia
    Article Snippet: Antibodies against FLT3 (3462; clone 8F2), phospho-FLT3 (3464; clone 30D4), STAT5 (94025; clone D206Y), phospho-STAT5 (4322; clone D47E7), AKT (4691; clone C67E7), phospho-AKT (4060; clone D9E), ERK1/2 (4695; clone 137F5), phospho-EKR1/2 (4370; clone D.13.14.4E), S6K (2708; clone 49D7), phospho-S6K (97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST).(97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST). ... Drugs were obtained from the following sources: TP-0903 (Tolero Pharmaceuticals), gilteritinib (ChemieTek), crenolanib (AROG Pharmaceuticals LLC), midostaurin (LC Laboratories), quizartinib (ChemieTek), sorafenib (LC Laboratories), and RG-7388 (MedChemExpress).. Human and mouse cytokines were purchased from Peprotech.Human and mouse cytokines were purchased from Peprotech.

    Comparison:

    Article Title: AXL tyrosine kinase inhibitor TP-0903 induces ROS trigger neuroblastoma cell apoptosis via targeting the miR-335-3p/DKK1 expression
    Article Snippet: TP-0903 (HY-12963) was purchased from MedChemExpress.. Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).

    Article Title: Mesenchymal-epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate.
    Article Snippet: Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section.. After three days of incubation, the medium was removed.After three days of incubation, the medium was removed.

    Article Title: Mesenchymal–epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate
    Article Snippet: (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays. .. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section. .. After three days of incubation, the medium was removed.

    Article Title: TP-0903 is active in models of drug-resistant acute myeloid leukemia
    Article Snippet: Antibodies against FLT3 (3462; clone 8F2), phospho-FLT3 (3464; clone 30D4), STAT5 (94025; clone D206Y), phospho-STAT5 (4322; clone D47E7), AKT (4691; clone C67E7), phospho-AKT (4060; clone D9E), ERK1/2 (4695; clone 137F5), phospho-EKR1/2 (4370; clone D.13.14.4E), S6K (2708; clone 49D7), phospho-S6K (97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST).(97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST). ... Drugs were obtained from the following sources: TP-0903 (Tolero Pharmaceuticals), gilteritinib (ChemieTek), crenolanib (AROG Pharmaceuticals LLC), midostaurin (LC Laboratories), quizartinib (ChemieTek), sorafenib (LC Laboratories), and RG-7388 (MedChemExpress).. Human and mouse cytokines were purchased from Peprotech.Human and mouse cytokines were purchased from Peprotech.

    Colony-forming Unit Assay:

    Article Title: AXL tyrosine kinase inhibitor TP-0903 induces ROS trigger neuroblastoma cell apoptosis via targeting the miR-335-3p/DKK1 expression
    Article Snippet: TP-0903 (HY-12963) was purchased from MedChemExpress.. Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).

    Article Title: Mesenchymal-epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate.
    Article Snippet: Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section.. After three days of incubation, the medium was removed.After three days of incubation, the medium was removed.

    Article Title: Mesenchymal–epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate
    Article Snippet: (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays. .. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section. .. After three days of incubation, the medium was removed.

    Article Title: TP-0903 is active in models of drug-resistant acute myeloid leukemia
    Article Snippet: Antibodies against FLT3 (3462; clone 8F2), phospho-FLT3 (3464; clone 30D4), STAT5 (94025; clone D206Y), phospho-STAT5 (4322; clone D47E7), AKT (4691; clone C67E7), phospho-AKT (4060; clone D9E), ERK1/2 (4695; clone 137F5), phospho-EKR1/2 (4370; clone D.13.14.4E), S6K (2708; clone 49D7), phospho-S6K (97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST).(97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST). ... Drugs were obtained from the following sources: TP-0903 (Tolero Pharmaceuticals), gilteritinib (ChemieTek), crenolanib (AROG Pharmaceuticals LLC), midostaurin (LC Laboratories), quizartinib (ChemieTek), sorafenib (LC Laboratories), and RG-7388 (MedChemExpress).. Human and mouse cytokines were purchased from Peprotech.Human and mouse cytokines were purchased from Peprotech.

    Ex Vivo:

    Article Title: AXL tyrosine kinase inhibitor TP-0903 induces ROS trigger neuroblastoma cell apoptosis via targeting the miR-335-3p/DKK1 expression
    Article Snippet: TP-0903 (HY-12963) was purchased from MedChemExpress.. Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).

    Article Title: Mesenchymal-epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate.
    Article Snippet: Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section.. After three days of incubation, the medium was removed.After three days of incubation, the medium was removed.

    Article Title: Mesenchymal–epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate
    Article Snippet: (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays. .. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section. .. After three days of incubation, the medium was removed.

    Article Title: TP-0903 is active in models of drug-resistant acute myeloid leukemia
    Article Snippet: Antibodies against FLT3 (3462; clone 8F2), phospho-FLT3 (3464; clone 30D4), STAT5 (94025; clone D206Y), phospho-STAT5 (4322; clone D47E7), AKT (4691; clone C67E7), phospho-AKT (4060; clone D9E), ERK1/2 (4695; clone 137F5), phospho-EKR1/2 (4370; clone D.13.14.4E), S6K (2708; clone 49D7), phospho-S6K (97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST).(97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST). ... Drugs were obtained from the following sources: TP-0903 (Tolero Pharmaceuticals), gilteritinib (ChemieTek), crenolanib (AROG Pharmaceuticals LLC), midostaurin (LC Laboratories), quizartinib (ChemieTek), sorafenib (LC Laboratories), and RG-7388 (MedChemExpress).. Human and mouse cytokines were purchased from Peprotech.Human and mouse cytokines were purchased from Peprotech.

    Sequencing:

    Article Title: AXL tyrosine kinase inhibitor TP-0903 induces ROS trigger neuroblastoma cell apoptosis via targeting the miR-335-3p/DKK1 expression
    Article Snippet: TP-0903 (HY-12963) was purchased from MedChemExpress.. Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).

    Article Title: Mesenchymal-epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate.
    Article Snippet: Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section.. After three days of incubation, the medium was removed.After three days of incubation, the medium was removed.

    Article Title: Mesenchymal–epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate
    Article Snippet: (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays. .. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section. .. After three days of incubation, the medium was removed.

    Article Title: TP-0903 is active in models of drug-resistant acute myeloid leukemia
    Article Snippet: Antibodies against FLT3 (3462; clone 8F2), phospho-FLT3 (3464; clone 30D4), STAT5 (94025; clone D206Y), phospho-STAT5 (4322; clone D47E7), AKT (4691; clone C67E7), phospho-AKT (4060; clone D9E), ERK1/2 (4695; clone 137F5), phospho-EKR1/2 (4370; clone D.13.14.4E), S6K (2708; clone 49D7), phospho-S6K (97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST).(97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST). ... Drugs were obtained from the following sources: TP-0903 (Tolero Pharmaceuticals), gilteritinib (ChemieTek), crenolanib (AROG Pharmaceuticals LLC), midostaurin (LC Laboratories), quizartinib (ChemieTek), sorafenib (LC Laboratories), and RG-7388 (MedChemExpress).. Human and mouse cytokines were purchased from Peprotech.Human and mouse cytokines were purchased from Peprotech.

    Mutagenesis:

    Article Title: AXL tyrosine kinase inhibitor TP-0903 induces ROS trigger neuroblastoma cell apoptosis via targeting the miR-335-3p/DKK1 expression
    Article Snippet: TP-0903 (HY-12963) was purchased from MedChemExpress.. Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).

    Article Title: Mesenchymal-epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate.
    Article Snippet: Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section.. After three days of incubation, the medium was removed.After three days of incubation, the medium was removed.

    Article Title: Mesenchymal–epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate
    Article Snippet: (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays. .. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section. .. After three days of incubation, the medium was removed.

    Article Title: TP-0903 is active in models of drug-resistant acute myeloid leukemia
    Article Snippet: Antibodies against FLT3 (3462; clone 8F2), phospho-FLT3 (3464; clone 30D4), STAT5 (94025; clone D206Y), phospho-STAT5 (4322; clone D47E7), AKT (4691; clone C67E7), phospho-AKT (4060; clone D9E), ERK1/2 (4695; clone 137F5), phospho-EKR1/2 (4370; clone D.13.14.4E), S6K (2708; clone 49D7), phospho-S6K (97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST).(97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST). ... Drugs were obtained from the following sources: TP-0903 (Tolero Pharmaceuticals), gilteritinib (ChemieTek), crenolanib (AROG Pharmaceuticals LLC), midostaurin (LC Laboratories), quizartinib (ChemieTek), sorafenib (LC Laboratories), and RG-7388 (MedChemExpress).. Human and mouse cytokines were purchased from Peprotech.Human and mouse cytokines were purchased from Peprotech.

    Reverse Transcription Polymerase Chain Reaction:

    Article Title: AXL tyrosine kinase inhibitor TP-0903 induces ROS trigger neuroblastoma cell apoptosis via targeting the miR-335-3p/DKK1 expression
    Article Snippet: TP-0903 (HY-12963) was purchased from MedChemExpress.. Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).Chemicals and reagents without specific indication were purchased from Sigma-Aldrich (St. Louis, MO, USA).

    Article Title: Mesenchymal-epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate.
    Article Snippet: Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.Cell viability was analysed according to the manufacturer’s protocols for MTT (3-(4,5- dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays.. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section.. After three days of incubation, the medium was removed.After three days of incubation, the medium was removed.

    Article Title: Mesenchymal–epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate
    Article Snippet: (Sigma Aldrich) or MTS (3-(4,5- dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (Abcam, Waltham, MA, USA) assays. .. In brief, cells were seeded in 96-well plates at 70%-80% confluence and treated or mock-treated with various concentrations of ART (Sigma-Aldrich), TP-0903 (MedChemExpress, Monmouth, NJ, USA), or their different combinations as described in the Results section. .. After three days of incubation, the medium was removed.

    Article Title: TP-0903 is active in models of drug-resistant acute myeloid leukemia
    Article Snippet: Antibodies against FLT3 (3462; clone 8F2), phospho-FLT3 (3464; clone 30D4), STAT5 (94025; clone D206Y), phospho-STAT5 (4322; clone D47E7), AKT (4691; clone C67E7), phospho-AKT (4060; clone D9E), ERK1/2 (4695; clone 137F5), phospho-EKR1/2 (4370; clone D.13.14.4E), S6K (2708; clone 49D7), phospho-S6K (97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST).(97596; clone D5U10), S6RP (2217; clone 5G10), phospho-S6RP (4858; D57.2.2E), pAURKA/B/C (2914; clone D13A11), AURKA (91590; clone D3V7T), AURKB (3094; clone N/A), vinculin (13901; clone E1E9V), GAPDH (5174S; clone D16H11), MCL (39224; clone D5V5L), and HRP-conjugate secondary anti-rabbit (7074 /clone N/A) were obtained from Cell Signaling Technology (CST). ... Drugs were obtained from the following sources: TP-0903 (Tolero Pharmaceuticals), gilteritinib (ChemieTek), crenolanib (AROG Pharmaceuticals LLC), midostaurin (LC Laboratories), quizartinib (ChemieTek), sorafenib (LC Laboratories), and RG-7388 (MedChemExpress).. Human and mouse cytokines were purchased from Peprotech.Human and mouse cytokines were purchased from Peprotech.



    Similar Products

    tp 0903  (MedChemExpress)
    94
    MedChemExpress tp 0903
    A Structure of <t>TP-0903.</t> B – D Normal proximal tubular HK-2 and NB SH-SY5Y and Neuro-2a cells were treated with TP-0903 at serial concentrations for 24 h, and then the cell growth was determined using MTT assay. Cell growth was presented as percentage of control (0 μM, 100%). E Apoptosis assay using Annexin V/PI staining and flow cytometric analysis, ( F ) mitochondrial membrane potential (MMP) analysis, or ( G ) Western blot for apoptotic signaling cascade. Quantitative analysis of apoptotic cells or loss of MMP cells was presented as a percentage of total cells. Protein levels were semi-quantitated by densitometric analysis. GAPDH was used as internal control. * and ** P < 0.05 and P < 0.01 as compared to control.
    Tp 0903, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tp+0903/Dubermatinib/pmc12350951-177-0-5
    Average 94 stars, based on 1 article reviews
    tp 0903 - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    tp 0903  (Selleck Chemicals)
    93
    Selleck Chemicals tp 0903
    A Structure of <t>TP-0903.</t> B – D Normal proximal tubular HK-2 and NB SH-SY5Y and Neuro-2a cells were treated with TP-0903 at serial concentrations for 24 h, and then the cell growth was determined using MTT assay. Cell growth was presented as percentage of control (0 μM, 100%). E Apoptosis assay using Annexin V/PI staining and flow cytometric analysis, ( F ) mitochondrial membrane potential (MMP) analysis, or ( G ) Western blot for apoptotic signaling cascade. Quantitative analysis of apoptotic cells or loss of MMP cells was presented as a percentage of total cells. Protein levels were semi-quantitated by densitometric analysis. GAPDH was used as internal control. * and ** P < 0.05 and P < 0.01 as compared to control.
    Tp 0903, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tp+0903/Dubermatinib(TP-0903)/pm40829740-69-13-29
    Average 93 stars, based on 1 article reviews
    tp 0903 - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    tp-0903  (Selleck Chemicals)
    90
    Selleck Chemicals tp-0903
    A Structure of <t>TP-0903.</t> B – D Normal proximal tubular HK-2 and NB SH-SY5Y and Neuro-2a cells were treated with TP-0903 at serial concentrations for 24 h, and then the cell growth was determined using MTT assay. Cell growth was presented as percentage of control (0 μM, 100%). E Apoptosis assay using Annexin V/PI staining and flow cytometric analysis, ( F ) mitochondrial membrane potential (MMP) analysis, or ( G ) Western blot for apoptotic signaling cascade. Quantitative analysis of apoptotic cells or loss of MMP cells was presented as a percentage of total cells. Protein levels were semi-quantitated by densitometric analysis. GAPDH was used as internal control. * and ** P < 0.05 and P < 0.01 as compared to control.
    Tp 0903, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tp+0903/tp0903/pm40605022-48-9-10
    Average 90 stars, based on 1 article reviews
    tp-0903 - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    tp-0903  (Sumitomo Dainippon)
    90
    Sumitomo Dainippon tp-0903
    A Structure of <t>TP-0903.</t> B – D Normal proximal tubular HK-2 and NB SH-SY5Y and Neuro-2a cells were treated with TP-0903 at serial concentrations for 24 h, and then the cell growth was determined using MTT assay. Cell growth was presented as percentage of control (0 μM, 100%). E Apoptosis assay using Annexin V/PI staining and flow cytometric analysis, ( F ) mitochondrial membrane potential (MMP) analysis, or ( G ) Western blot for apoptotic signaling cascade. Quantitative analysis of apoptotic cells or loss of MMP cells was presented as a percentage of total cells. Protein levels were semi-quantitated by densitometric analysis. GAPDH was used as internal control. * and ** P < 0.05 and P < 0.01 as compared to control.
    Tp 0903, supplied by Sumitomo Dainippon, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tp+0903/tp+0903/pm40329335-72-0-4
    Average 90 stars, based on 1 article reviews
    tp-0903 - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    axl inhibitor tp 0903  (Selleck Chemicals)
    93
    Selleck Chemicals axl inhibitor tp 0903
    A Structure of <t>TP-0903.</t> B – D Normal proximal tubular HK-2 and NB SH-SY5Y and Neuro-2a cells were treated with TP-0903 at serial concentrations for 24 h, and then the cell growth was determined using MTT assay. Cell growth was presented as percentage of control (0 μM, 100%). E Apoptosis assay using Annexin V/PI staining and flow cytometric analysis, ( F ) mitochondrial membrane potential (MMP) analysis, or ( G ) Western blot for apoptotic signaling cascade. Quantitative analysis of apoptotic cells or loss of MMP cells was presented as a percentage of total cells. Protein levels were semi-quantitated by densitometric analysis. GAPDH was used as internal control. * and ** P < 0.05 and P < 0.01 as compared to control.
    Axl Inhibitor Tp 0903, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tp+0903/Dubermatinib(TP-0903)/pmc11597789-104-11-19
    Average 93 stars, based on 1 article reviews
    axl inhibitor tp 0903 - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    tp-0903 (dubermatinib)  (Tolero Inc)
    90
    Tolero Inc tp-0903 (dubermatinib)
    Overview of type I AXL inhibitors and their current status in clinical trials for AML
    Tp 0903 (Dubermatinib), supplied by Tolero Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tp+0903/tp+0903/pmc11453060-1-0-3
    Average 90 stars, based on 1 article reviews
    tp-0903 (dubermatinib) - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    tp-0903 tartaric acid  (Tolero Inc)
    90
    Tolero Inc tp-0903 tartaric acid
    Overview of type I AXL inhibitors and their current status in clinical trials for AML
    Tp 0903 Tartaric Acid, supplied by Tolero Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tp+0903/tp+0903/pmc11427241-45-0-7
    Average 90 stars, based on 1 article reviews
    tp-0903 tartaric acid - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    A Structure of TP-0903. B – D Normal proximal tubular HK-2 and NB SH-SY5Y and Neuro-2a cells were treated with TP-0903 at serial concentrations for 24 h, and then the cell growth was determined using MTT assay. Cell growth was presented as percentage of control (0 μM, 100%). E Apoptosis assay using Annexin V/PI staining and flow cytometric analysis, ( F ) mitochondrial membrane potential (MMP) analysis, or ( G ) Western blot for apoptotic signaling cascade. Quantitative analysis of apoptotic cells or loss of MMP cells was presented as a percentage of total cells. Protein levels were semi-quantitated by densitometric analysis. GAPDH was used as internal control. * and ** P < 0.05 and P < 0.01 as compared to control.

    Journal: Cell Death Discovery

    Article Title: AXL tyrosine kinase inhibitor TP-0903 induces ROS trigger neuroblastoma cell apoptosis via targeting the miR-335-3p/DKK1 expression

    doi: 10.1038/s41420-025-02681-9

    Figure Lengend Snippet: A Structure of TP-0903. B – D Normal proximal tubular HK-2 and NB SH-SY5Y and Neuro-2a cells were treated with TP-0903 at serial concentrations for 24 h, and then the cell growth was determined using MTT assay. Cell growth was presented as percentage of control (0 μM, 100%). E Apoptosis assay using Annexin V/PI staining and flow cytometric analysis, ( F ) mitochondrial membrane potential (MMP) analysis, or ( G ) Western blot for apoptotic signaling cascade. Quantitative analysis of apoptotic cells or loss of MMP cells was presented as a percentage of total cells. Protein levels were semi-quantitated by densitometric analysis. GAPDH was used as internal control. * and ** P < 0.05 and P < 0.01 as compared to control.

    Article Snippet: TP-0903 (HY-12963) was purchased from MedChemExpress.

    Techniques: MTT Assay, Control, Apoptosis Assay, Staining, Membrane, Western Blot

    Cells were treated with 100 nM TP-0903 for 24 h, and then subjected to total RNA extraction and gene expression analysis by RNA-seq analysis. A The heatmap of differentially expressed genes (DEGs) with -2≤ log 2 FC ≤ 2 in response to TP-0903 treatment. B The top 10 biological processes affected by the DEGs using Gene ontology analysis. P -values < 0.05 were indicated as red color. Cells were treated with 100 nM TP-0903 for 24 h, and then subjected to assessment of ( C ) protein levels or ( D ) mRNA expression levels by Western blotting or qRT-PCR analysis, respectively. E Protein levels and ( F ) mRNA expression levels of DKK1 among HK2 (Normal), Neuro-2a, and SH-SY5Y cells using Western blot and qRT-PCR, respectively. ** P < 0.01 as compared to control. G Violin plots of DKK1 gene expression in paired normal (green) and NB tumor (red) gene array data from the TNMplot database.

    Journal: Cell Death Discovery

    Article Title: AXL tyrosine kinase inhibitor TP-0903 induces ROS trigger neuroblastoma cell apoptosis via targeting the miR-335-3p/DKK1 expression

    doi: 10.1038/s41420-025-02681-9

    Figure Lengend Snippet: Cells were treated with 100 nM TP-0903 for 24 h, and then subjected to total RNA extraction and gene expression analysis by RNA-seq analysis. A The heatmap of differentially expressed genes (DEGs) with -2≤ log 2 FC ≤ 2 in response to TP-0903 treatment. B The top 10 biological processes affected by the DEGs using Gene ontology analysis. P -values < 0.05 were indicated as red color. Cells were treated with 100 nM TP-0903 for 24 h, and then subjected to assessment of ( C ) protein levels or ( D ) mRNA expression levels by Western blotting or qRT-PCR analysis, respectively. E Protein levels and ( F ) mRNA expression levels of DKK1 among HK2 (Normal), Neuro-2a, and SH-SY5Y cells using Western blot and qRT-PCR, respectively. ** P < 0.01 as compared to control. G Violin plots of DKK1 gene expression in paired normal (green) and NB tumor (red) gene array data from the TNMplot database.

    Article Snippet: TP-0903 (HY-12963) was purchased from MedChemExpress.

    Techniques: RNA Extraction, Gene Expression, RNA Sequencing, Expressing, Western Blot, Quantitative RT-PCR, Control

    Cells were transfected with siRNA against DKK1 (si-DKK1), treated with 50 nM TP-0903 for 24 h, and subjected to ( A ) immunodetection of cleaved PARP (C-PARP), cleaved caspase-3 (C-Caspase-3), and DKK1; ( B ) cell viability assay; or ( C ) cell apoptosis assay using Annexin V/PI staining and flow cytometric analysis. ** P < 0.01 as compared to control (si-NC, 0 nM). # P < 0.05 as compared to TP-0903 alone (50 nM). D Binding mode for docked ligand TP-0903 (cyan) was shown as stick representation in DKK1 (left panel). Structural domains of DKK1 and the amino acid residues interaction with TP-0903 were indicated. Binding affinity between TP-0903 and DKK1 was −6.0 kcal/mol.

    Journal: Cell Death Discovery

    Article Title: AXL tyrosine kinase inhibitor TP-0903 induces ROS trigger neuroblastoma cell apoptosis via targeting the miR-335-3p/DKK1 expression

    doi: 10.1038/s41420-025-02681-9

    Figure Lengend Snippet: Cells were transfected with siRNA against DKK1 (si-DKK1), treated with 50 nM TP-0903 for 24 h, and subjected to ( A ) immunodetection of cleaved PARP (C-PARP), cleaved caspase-3 (C-Caspase-3), and DKK1; ( B ) cell viability assay; or ( C ) cell apoptosis assay using Annexin V/PI staining and flow cytometric analysis. ** P < 0.01 as compared to control (si-NC, 0 nM). # P < 0.05 as compared to TP-0903 alone (50 nM). D Binding mode for docked ligand TP-0903 (cyan) was shown as stick representation in DKK1 (left panel). Structural domains of DKK1 and the amino acid residues interaction with TP-0903 were indicated. Binding affinity between TP-0903 and DKK1 was −6.0 kcal/mol.

    Article Snippet: TP-0903 (HY-12963) was purchased from MedChemExpress.

    Techniques: Transfection, Immunodetection, Viability Assay, Apoptosis Assay, Staining, Control, Binding Assay

    A Predicted binding site of miR-335-3p on 3’UTR of DKK1 gene. B Cells were treated with serial concentrations of TP-0903 for 24 h and subjected to assess miR-335-3p expression level by qRT-PCR. Neuro-2a cells were transfected with control-mimic or miR-335-mimic, treated with TP-0903, and subjected to ( C ) immunodetection of DKK1 and cleaved PARP (C-PARP) using Western blot analysis, ( D ) cell viability assay, ( E ) qRT-PCR to determine miR-335-3p expression level, ( F ) quantitation of signals on Western blots, or ( G ) cell apoptosis assay using Annexin V/PI staining and flow cytometric analysis. ** P < 0.01 as compared to control. # P < 0.05 as compared to TP-0903 alone (50 nM).

    Journal: Cell Death Discovery

    Article Title: AXL tyrosine kinase inhibitor TP-0903 induces ROS trigger neuroblastoma cell apoptosis via targeting the miR-335-3p/DKK1 expression

    doi: 10.1038/s41420-025-02681-9

    Figure Lengend Snippet: A Predicted binding site of miR-335-3p on 3’UTR of DKK1 gene. B Cells were treated with serial concentrations of TP-0903 for 24 h and subjected to assess miR-335-3p expression level by qRT-PCR. Neuro-2a cells were transfected with control-mimic or miR-335-mimic, treated with TP-0903, and subjected to ( C ) immunodetection of DKK1 and cleaved PARP (C-PARP) using Western blot analysis, ( D ) cell viability assay, ( E ) qRT-PCR to determine miR-335-3p expression level, ( F ) quantitation of signals on Western blots, or ( G ) cell apoptosis assay using Annexin V/PI staining and flow cytometric analysis. ** P < 0.01 as compared to control. # P < 0.05 as compared to TP-0903 alone (50 nM).

    Article Snippet: TP-0903 (HY-12963) was purchased from MedChemExpress.

    Techniques: Binding Assay, Expressing, Quantitative RT-PCR, Transfection, Control, Immunodetection, Western Blot, Viability Assay, Quantitation Assay, Apoptosis Assay, Staining

    A Cells were treated with TP-0903 for 24 h and subjected to ROS assay. Cells were treated with 50 nM TP-0903 or TP-0903 combined with NAC for 24 h and subjected to ( B ) ROS assay, ( C ) apoptosis assay using Annexin V/PI staining and flow cytometric analysis, ( D ) immunodetection of C-PARP and DKK1 by Western blot, or ( E ) qRT-PCR to determine miR-335-3p expression level. GAPDH was used as internal control. Signals were semi-quantitated by densitometric analysis. ** P < 0.01 as compared to control. # P < 0.05 as compared to TP-0903 alone (50 nM). Scale bar=20 μm.

    Journal: Cell Death Discovery

    Article Title: AXL tyrosine kinase inhibitor TP-0903 induces ROS trigger neuroblastoma cell apoptosis via targeting the miR-335-3p/DKK1 expression

    doi: 10.1038/s41420-025-02681-9

    Figure Lengend Snippet: A Cells were treated with TP-0903 for 24 h and subjected to ROS assay. Cells were treated with 50 nM TP-0903 or TP-0903 combined with NAC for 24 h and subjected to ( B ) ROS assay, ( C ) apoptosis assay using Annexin V/PI staining and flow cytometric analysis, ( D ) immunodetection of C-PARP and DKK1 by Western blot, or ( E ) qRT-PCR to determine miR-335-3p expression level. GAPDH was used as internal control. Signals were semi-quantitated by densitometric analysis. ** P < 0.01 as compared to control. # P < 0.05 as compared to TP-0903 alone (50 nM). Scale bar=20 μm.

    Article Snippet: TP-0903 (HY-12963) was purchased from MedChemExpress.

    Techniques: ROS Assay, Apoptosis Assay, Staining, Immunodetection, Western Blot, Quantitative RT-PCR, Expressing, Control

    Balb/c nude mice were inoculated with Neuro-2a cells, and then oral administration of PBS or TP-0903 (10 mg/kg) every 3 days for 20 days. A Representative tumors and ( C ) tumor weights in xenografted mice. Changes in ( B ) tumor volume and ( D ) mouse body weights during the 20-day treatment period. Tumors were acquired and subjected to ( E ) Western blot or ( F ) qRT-PCR to assess DKK1 protein and mRNA expression level, respectively. G IHC assay to assess cell proliferation and DKK1 expression in tumor tissues. H H&E staining to assess tissue morphology. * and **, P < 0.05 and P < 0.01 as compared to control group.

    Journal: Cell Death Discovery

    Article Title: AXL tyrosine kinase inhibitor TP-0903 induces ROS trigger neuroblastoma cell apoptosis via targeting the miR-335-3p/DKK1 expression

    doi: 10.1038/s41420-025-02681-9

    Figure Lengend Snippet: Balb/c nude mice were inoculated with Neuro-2a cells, and then oral administration of PBS or TP-0903 (10 mg/kg) every 3 days for 20 days. A Representative tumors and ( C ) tumor weights in xenografted mice. Changes in ( B ) tumor volume and ( D ) mouse body weights during the 20-day treatment period. Tumors were acquired and subjected to ( E ) Western blot or ( F ) qRT-PCR to assess DKK1 protein and mRNA expression level, respectively. G IHC assay to assess cell proliferation and DKK1 expression in tumor tissues. H H&E staining to assess tissue morphology. * and **, P < 0.05 and P < 0.01 as compared to control group.

    Article Snippet: TP-0903 (HY-12963) was purchased from MedChemExpress.

    Techniques: Western Blot, Quantitative RT-PCR, Expressing, Staining, Control

    TP-0903 promotes ROS generation, upregulates miR-335-3p expression, consequently downregulating DKK1 expression and leading to cell apoptosis.

    Journal: Cell Death Discovery

    Article Title: AXL tyrosine kinase inhibitor TP-0903 induces ROS trigger neuroblastoma cell apoptosis via targeting the miR-335-3p/DKK1 expression

    doi: 10.1038/s41420-025-02681-9

    Figure Lengend Snippet: TP-0903 promotes ROS generation, upregulates miR-335-3p expression, consequently downregulating DKK1 expression and leading to cell apoptosis.

    Article Snippet: TP-0903 (HY-12963) was purchased from MedChemExpress.

    Techniques: Expressing

    Overview of type I AXL inhibitors and their current status in clinical trials for AML

    Journal: Experimental Hematology & Oncology

    Article Title: AXL as immune regulator and therapeutic target in Acute Myeloid Leukemia: from current progress to novel strategies

    doi: 10.1186/s40164-024-00566-8

    Figure Lengend Snippet: Overview of type I AXL inhibitors and their current status in clinical trials for AML

    Article Snippet: TP-0903 (Dubermatinib) , Tolero Pharmaceuticals , AXL, FLT3 , 27 nM (in vitro) , NCT03013998 , Ib/II , AML , Biomarker-based multidrug therapy , Recruiting.

    Techniques: Clinical Proteomics, In Vitro, Biomarker Discovery, Mutagenesis